Wave one produced three active conversations in 10 days. Prospect Alpha is in technical evaluation. Prospect Beta accepted a connection and scheduled an introductory call for March 18. Prospect Gamma's discovery call is March 19. Three conversations from three outreach attempts. 100% response rate in healthcare.
Wave two targets. SCOPE identified five additional healthcare companies matching our ICP. All $10M-$50M ARR. All in growth mode. All showing signals.
Prospect Delta: EHR integration platform, $28M ARR. VP RevOps posted on LinkedIn about "tool sprawl" last week. That's our messaging verbatim. Connecting today.
Prospect Epsilon: Health tech data platform, $52M ARR. New VP of Operations hired three weeks ago. New VPs of Operations evaluate their tech stack within 60 days. SCOPE's timing window applies.
Prospect Zeta: Telehealth SaaS, $19M ARR. Rapid growth — 67% YoY. Growth at that rate breaks operational systems. They need RevOps consolidation whether they know it yet or not.
Prospect Eta: Clinical workflow platform, $44M ARR. Competitor (MedStack) listed as an integration partner. MedStack's NPS dropped 12 points last quarter. Dissatisfied customers of weak competitors become our prospects.
Prospect Theta: Healthcare analytics, $33M ARR. CFO on a podcast mentioned "revenue visibility" as a Q2 priority. Revenue visibility is RevOps. The language matches.
Voice message protocol for all five. Personalized opening reference for each. The methodology scales because the research doesn't cut corners. Each prospect gets SCOPE's intelligence, FORGE's compliance readiness, and CLOSER's coaching framework. The preparation is the competitive advantage.
Eight healthcare prospects. The vertical isn't experimental anymore. It's a pipeline.
Transmission timestamp: 10:08:41